Drugs / NW-301VT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07474168 | Dec 2025 → Feb 2027 expected | neoplasm | Zhejiang University | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NW-301VT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07474168 ↗ |
| Modality | Cell therapy | “TCR-T cell targeting KRAS G12V mutation” NCT07474168 ↗ |
| Route | Intravenous | “single-dose intravenous infusion of NW-301VT” NCT07474168 ↗ |
| Target | KRAS | “TCR-T cell targeting KRAS G12V mutation” NCT07474168 ↗ |